Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents

Julio Rosenstock, Richard Bergenstal, Ralph A Defronzo, Irl B Hirsch, David Klonoff, Anders H Boss, David Kramer, Richard Petrucci, Wen Yu, Brian Levy, 0008 Study Group, O J Bizzozero Jr, L Blonde, A Drexler, S Engel, V Fonseca, R Henry, D Lorber, J Marks, J McGill, W Petit, P Raskin, S Schwartz, G Uwaifo, M Warren, D Weiss, H Zisser, Julio Rosenstock, Richard Bergenstal, Ralph A Defronzo, Irl B Hirsch, David Klonoff, Anders H Boss, David Kramer, Richard Petrucci, Wen Yu, Brian Levy, 0008 Study Group, O J Bizzozero Jr, L Blonde, A Drexler, S Engel, V Fonseca, R Henry, D Lorber, J Marks, J McGill, W Petit, P Raskin, S Schwartz, G Uwaifo, M Warren, D Weiss, H Zisser

Abstract

Objective: This double-blind, placebo-controlled, randomized, multicenter, parallel-group study compared the efficacy, safety, and tolerability of Technosphere insulin with Technosphere powder as placebo in insulin-naive type 2 diabetic patients whose diabetes was suboptimally controlled with oral antidiabetic agents.

Research design and methods: Patients (n = 126) were randomly assigned to 12 weeks of therapy with Technosphere insulin or Technosphere powder after lifestyle education on nutrition, exercise, and instructions on inhaler use. The primary efficacy outcome was change in A1C from baseline to study end, and the secondary efficacy outcome was area under the curve for postprandial glucose levels during a meal test at treatment weeks 4, 8, and 12.

Results: A1C reduction from a mean baseline of 7.9% was greater with Technosphere insulin than with Technosphere powder (-0.72 vs. -0.30%; P = 0.003). Postprandial glucose excursions were reduced by 56% with Technosphere insulin compared with baseline, and maximal postprandial glucose levels were reduced by 43% compared with Technosphere powder. Incidences of hypoglycemia, hyperglycemia, cough, and other adverse events were low in both groups. Body weight was unchanged in both groups.

Conclusions: Technosphere insulin was well tolerated and demonstrated significant improvement in glycemic control with clinically meaningful reductions in A1C levels and postprandial glucose concentrations after 12 weeks of treatment.

Trial registration: ClinicalTrials.gov NCT00511602.

Figures

Figure 1
Figure 1
Subject disposition.
Figure 2
Figure 2
A: Reductions in A1C. B: Postprandial glucose excursions. ▪, Technosphere placebo; □, Technosphere insulin.

References

    1. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B: Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29:1963–1972, 2006
    1. Riddle MC, Rosenstock J, Gerich J: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26:3080–3086, 2003
    1. Yki-Jarvinen H: Combination therapies with insulin in type 2 diabetes. Diabetes Care 24:758–767, 2001
    1. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T: Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 371:1073–1084, 2008
    1. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 357:1716–1730, 2007
    1. Hunt LM, Valenzuela MA, Pugh JA: NIDDM patients’ fears and hopes about insulin therapy: the basis of patient reluctance. Diabetes Care 20:292–298, 1997
    1. Korytkowski M: When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 26 (Suppl. 3):S18–S24, 2002
    1. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinebreil L: Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 28:2673–2679, 2005
    1. Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA: Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 27:1318–1323, 2004
    1. Leone-Bay A, Grant M: Technosphere®/insulin: mimicking endogenous insulin release. In Modified-Release Drug Delivery Technology. Vol. 2, 2nd ed. Rathbone M, Hadgraft J, Roberts M, Lane M, Eds. New York, Informa Healthcare USA, 2008
    1. Steiner S, Pfützner A, Wilson BR, Harzer O, Heinemann L, Rave K: Technosphere/insulin—proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes 110:17–21, 2002
    1. Pfützner A, Forst T: Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism. Expert Opin Drug Deliv 2:1097–1106, 2005
    1. Rave K, Heise T, Pfützner A, Boss AH: Coverage of postprandial blood glucose excursions with inhaled Technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes. Diabetes Care 30:2307–2308, 2007
    1. Boss AH, Rave K, Cheatham WW, Heise T: Inhaled Technosphere/Insulin: glucose elimination at the right time (abstract 443–P)? Diabetes 54 (Suppl. 1):A109, 2005
    1. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group, European Diabetes Epidemiology Group, Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe. Lancet 354:617–621, 1999
    1. Monnier L, Lapinski H, Colette C: Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 26:881–885, 2003
    1. Hankinson JL, Odencrantz JR, Fedan KB: Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 159:179–187, 1999
    1. Miller A, Thornton JC, Warshaw R, Anderson H, Teirstein AS, Selikoff IJ: Single breath diffusing capacity in a representative sample of the population of Michigan, a large industrial state: predicted values, lower limits of normal, and frequencies of abnormality by smoking history. Am Rev Respir Dis 127:270–277, 1983
    1. American Diabetes Association: Standards of medical care in diabetes—2007. Diabetes Care 30 (Suppl. 1):S4–S41, 2007
    1. Gale EA, Beattie S, Hu J, Koivisto V, Tan M: Recruitment to a clinical trial improves glycemic control in patients with diabetes. Diabetes Care 30:2989–2992, 2007
    1. Heinemann L, Heise T: Current status of the development of inhaled insulin. Br J Diabetes Vasc Dis 4:295–301, 2004
    1. Rave KM, Heise T, Pfützner A, Steiner S, Heinemann L: Results of a dose-response study with a new pulmonary insulin formulation and inhaler (Abstract 305–PP). Diabetes 49 (Suppl. 1):A75, 2000

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다